“A divided Congress in a presidential election year may seem an unlikely setting for the first major drug-pricing reform in decades, but over the past year common goals and designs have emerged to set up a rare opportunity,” Joe Grogan, Director of the White House Domestic Policy Council, writes in The Wall Street Journal.
“President Trump has made lowering prescription-drug costs a priority and is willing to invest political capital to work with both parties . . . Congress should capitalize on this opportunity and work with the administration to reject special interests, reject partisan posturing, and provide relief to the American people.” Click here to read more. |
|
No comments:
Post a Comment